Microdosing GLP-1 weight loss drugs like semaglutide may come with benefits like lower cost and fewer side effects, but doctors urge caution.

The new guidelines are yet another sign that GLP-1 drugs like Ozempic are likely to continue soaring in popularity as a weight loss treatment

Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that just succeeded in late-stage testing in China.

A Lilly experimental weight loss pill showed superior blood sugar control in diabetic patients across two late-stage clinical trials

Eli Lilly (NYSE: LLY) is now known for its weight loss drugs. Its stock has risen 150% since mid-2022 because of high demand for Mounjaro (tirzepatide approved to treat type 2 diabetes) and Zepbound (tirzepatide approved for weight loss). For many investors, that's the whole story: Lilly found a big health trend and is making huge profits.

Kailera Therapeutics has raised $600 million to take its lead obesity program into phase 3. The series B round continues the meteoric rise of Kailera, which exited stealth with $400 million and ex-China rights to a clutch of obesity candidates barely 12 months ago.